HCCR-1 is a Novel Prognostic Indicator for Gastric Cancer and Promotes Cell Proliferation

Overview

Journal J Cancer

Specialty Oncology

Date 2019 Jul 12

PMID 31293658

Citations 5

Authors

Liang-Fei Zhu

Peng Ma

Yi-Lin Hu

Ying Feng

Peng Li

Hua Wang

Yi-Bing Guo

Qin-Sheng Mao

Wan-Jiang Xue

Affiliations

Soon will be listed here.

Abstract

The role of the human cervical cancer oncogene () in the development of various tumors has been elucidated; however, its expression and function in gastric cancer remains largely unknown. Accordingly, the expression of HCCR-1 and epidermal growth factor (EGF) were detected in paired gastric cancer tissues and cell lines by western blotting (WB) and immunohistochemistry (IHC). Furthermore, the correlations between HCCR-1 expression in 209 gastric cancer tissues and the clinicopathological features and disease prognosis were analyzed. A stable HCCR-1 overexpression cell line was established, and the influence of increased HCCR-1 expression on the growth of gastric cancer cells was observed and . The expression of HCCR-1 generally increased in gastric cancer tissues. Further, increased HCCR-1 expression in gastric cancer tissues was associated with tumor T stage and was an independent factor that influenced poor postoperative prognosis in gastric cancer patients. A positive correlation was also detected between the expression of EGF and HCCR-1 in a time- and dose-dependent manner. The overexpression of HCCR-1 might enhance the growth rate of gastric cancer cells , increase the number of colony forming units, and promote the growth, volume, and weight of subcutaneous tumors in nude mice. In conclusion, is a gastric cancer oncogene, and its increased expression plays a critical role in the occurrence and development of gastric cancer. Hence, HCCR-1 could serve as a valuable marker for the postoperative prognostic assessment of gastric cancer patients.

Citing Articles

The clinicopathological significance of BRI3BP in women with invasive breast cancer.

Aljohani A, Aljahdali I, Alsalmi O, Alsuwat M, Alsharif A, Alzahrani K Transl Cancer Res. 2025; 13(12):6837-6849.

PMID: 39816562 PMC: 11730447. DOI: 10.21037/tcr-24-1113.

ADAMTS7 Enhances Gastric Cancer Growth and Metastasis by Triggering the NF-κB Signaling Pathway.

Chen S, He J, Gao H, Gao X, Dai L, Chen J J Cancer. 2025; 16(3):1008-1019.

PMID: 39781347 PMC: 11705055. DOI: 10.7150/jca.103093.

β-Elemene promotes ferroptosis and reverses radioresistance in gastric cancer by inhibiting the OTUB1-GPX4 interaction.

He J, Li M, Bao J, Peng Y, Xue W, Chen J Front Pharmacol. 2024; 15:1469180.

PMID: 39484165 PMC: 11524901. DOI: 10.3389/fphar.2024.1469180.

mir-605-3p prevents liver premetastatic niche formation by inhibiting angiogenesis via decreasing exosomal nos3 release in gastric cancer.

Hu Y, Zang W, Feng Y, Mao Q, Chen J, Zhu Y Cancer Cell Int. 2024; 24(1):184.

PMID: 38802855 PMC: 11131241. DOI: 10.1186/s12935-024-03359-5.

ECHDC2 inhibits the proliferation of gastric cancer cells by binding with NEDD4 to degrade MCCC2 and reduce aerobic glycolysis.

He J, Yi J, Ji L, Dai L, Chen Y, Xue W Mol Med. 2024; 30(1):69.

PMID: 38783226 PMC: 11118108. DOI: 10.1186/s10020-024-00832-9.

References

Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2000; 103(2):211-25. DOI: 10.1016/s0092-8674(00)00114-8. View

Ko J, Han Lee Y, Hwang S, Lee Y, Shin S, Hwang J . Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization. Oncogene. 2003; 22(30):4679-89. DOI: 10.1038/sj.onc.1206624. View

Yoon S, Lim N, Ha S, Park Y, Choi J, Chung K . The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res. 2004; 64(15):5434-41. DOI: 10.1158/0008-5472.CAN-03-3665. View

Jung S, Park H, Lee I, Namkoong H, Shin S, Cho G . The HCCR oncoprotein as a biomarker for human breast cancer. Clin Cancer Res. 2005; 11(21):7700-8. DOI: 10.1158/1078-0432.CCR-04-2609. View

Shin S, Chung Y, Oh S, Jeon H, Hwang L, Namkoong H . HCCR-1-interacting molecule "deleted in polyposis 1" plays a tumor-suppressor role in colon carcinogenesis. Gastroenterology. 2006; 130(7):2074-86. DOI: 10.1053/j.gastro.2006.03.055. View

Cho G, Shin S, Namkoong H, Kim H, Ha S, Hur S . The phosphatidylinositol 3-kinase/Akt pathway regulates the HCCR-1 oncogene expression. Gene. 2006; 384:18-26. DOI: 10.1016/j.gene.2006.07.006. View

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

Xue W, Li C, Zhou X, Guan H, Qin L, Li P . RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County. J Gastroenterol Hepatol. 2007; 23(9):1448-58. DOI: 10.1111/j.1440-1746.2007.05067.x. View

De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello M, Aldinucci D . The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2007; 214(3):559-67. DOI: 10.1002/jcp.21260. View

10.

Caraglia M, Marra M, Meo G, Addeo S, Tagliaferri P, Budillon A . EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy. Recent Pat Anticancer Drug Discov. 2008; 1(2):209-22. DOI: 10.2174/157489206777442250. View

11.

Ha S, Lee Y, Shin S, Kim H, Kim S, Namkoong H . Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status. BMC Cancer. 2009; 9:51. PMC: 2672955. DOI: 10.1186/1471-2407-9-51. View

12.

Xu Z, Zhang Y, Jiang J, Yang Y, Shi R, Hao B . Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells. BMC Cancer. 2010; 10:161. PMC: 2880295. DOI: 10.1186/1471-2407-10-161. View

13.

Ha S, Kim H, Yoo J, Kim S, Shin S, Lee Y . Transdifferentiation-inducing HCCR-1 oncogene. BMC Cell Biol. 2010; 11:49. PMC: 2909153. DOI: 10.1186/1471-2121-11-49. View

14.

Jirun P, Zhang G, Kim H, Ha S, Zhongtian J, Shishi Q . Clinical utility of alpha fetoprotein and HCCR-1, alone or in combination, in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Dis Markers. 2011; 30(6):307-15. PMC: 3825078. DOI: 10.3233/DMA-2011-0789. View

15.

Qiao S, Cui Z, Gong L, Han H, Chen P, Guo L . Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology. 2011; 58(110-111):1718-24. DOI: 10.5754/hge11124. View

16.

Zhang G, Ha S, Kim H, Yoo J, Kim S, Lee Y . Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study. Dis Markers. 2012; 32(4):265-71. PMC: 3826799. DOI: 10.3233/DMA-2011-0878. View

17.

Liu Y, Li K, Ren Z, Li S, Zhang H, Fan Q . Clinical implication of elevated human cervical cancer oncogene-1 expression in esophageal squamous cell carcinoma. J Histochem Cytochem. 2012; 60(7):512-20. PMC: 3460349. DOI: 10.1369/0022155412444437. View

18.

Ilson D . Angiogenesis in gastric cancer: hitting the target?. Lancet. 2013; 383(9911):4-6. DOI: 10.1016/S0140-6736(13)61892-9. View

19.

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

20.

Mei H, Lian S, Zhang S, Wang W, Mao Q, Wang H . High expression of ROR2 in cancer cell correlates with unfavorable prognosis in colorectal cancer. Biochem Biophys Res Commun. 2014; 453(4):703-9. DOI: 10.1016/j.bbrc.2014.09.141. View